Watch SMMT. Know when insiders buy.
One email the day a filing lands. Free.
SMMT
Summit Therapeutics Inc.
15.83
−0.26 −1.62%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
63
WATCH · shorts 26, street 100
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
+19.2
avg pts vs index · 1 scored
MKT CAP $12.6BP/E —DIV YIELD —FCF YIELD -3.64%REV TTM —NET INCOME −$856.1MNET CASH —52W 12.43 – 26.38SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | — | −$215.7M | — | -0.28 | −$141.1M | $909K | −$142M | Jul 23 |
| Q1 2026 · Mar 31 | — | — | — | — | −$189.4M | — | -0.24 | −$122.3M | $245K | −$122.5M | Jul 23 |
| Q4 2025 · Dec 31derived | — | — | — | — | −$219.2M | — | -0.28 | −$101.9M | $164K | −$102.1M | Feb 23 |
| Q3 2025 · Sep 30 | — | — | — | — | −$231.8M | — | -0.31 | −$93.1M | $71K | −$93.2M | Oct 20 |
| Q2 2025 · Jun 30 | — | — | — | — | −$565.7M | — | -0.76 | −$66.7M | $0 | −$66.7M | Jul 23 |
| Q1 2025 · Mar 31 | — | — | — | — | −$62.9M | — | -0.09 | −$61.2M | $422K | −$61.6M | Jul 23 |
| Q4 2024 · Dec 31derived | $0 | — | — | −$65.6M | −$61.2M | — | -0.09 | −$48.7M | $14K | −$48.7M | Feb 23 |
| Q3 2024 · Sep 30 | $0 | — | — | −$58.4M | −$56.3M | — | -0.08 | −$30.3M | $58K | −$30.4M | Oct 20 |
| Q2 2024 · Jun 30 | — | — | — | −$59.6M | −$60.4M | — | -0.09 | −$33M | $63K | −$33.1M | Oct 20 |
| Q1 2024 · Mar 31 | — | — | — | −$42.4M | −$43.5M | — | -0.06 | −$30.1M | $4K | −$30.1M | Oct 20 |
| Q4 2023 · Dec 31derived | $0 | — | — | −$36.2M | −$36.6M | — | -0.01 | −$19.5M | $2K | −$19.5M | Feb 23 |
| Q3 2023 · Sep 30 | $0 | — | — | −$20.5M | −$21.3M | — | -0.03 | −$14.9M | $53K | −$14.9M | Oct 30 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | — | −$1.1B | — | -1.44 | −$322.9M | $657K | −$323.6M | — | — |
| FY2024 · to Dec 31 | $0 | — | −$226M | −$221.3M | — | -0.31 | −$142.1M | $139K | −$142.2M | — | — |
| FY2023 · to Dec 31 | $0 | — | −$609.6M | −$614.9M | — | -0.99 | −$76.8M | $128K | −$76.9M | — | — |
| FY2022 · to Dec 31 | $705K | — | −$72.1M | −$78.8M | -11174.8% | -0.41 | −$41.6M | $624K | −$42.2M | — | — |
| FY2021 · to Dec 31 | $1.8M | — | −$86.2M | −$88.6M | -4897.8% | -0.67 | −$72.6M | $306K | −$72.9M | — | — |
| FY2020 · to Dec 31 | $860K | — | −$53.2M | −$52.7M | -6127.6% | -0.76 | −$48.1M | $421K | −$48.5M | — | $0 |
Every number comes from Summit Therapeutics Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.